Novo Nordisk liraglutide delayed
Executive Summary
FDA's review of Novo Nordisk's diabetes agent liraglutide will probably be delayed "by a couple of months" for an advisory committee review of the GLP-1 analogue, the company reports Sept. 5. The March 2, 2009 meeting is three weeks before liraglutide's user fee date (1"The Pink Sheet" DAILY, Aug. 8, 2008). Liraglutide may be subject to extra scrutiny after recent reports of pancreatitis from Amylin/Lilly's GLP-1 Byetta (exenatide)
You may also be interested in...
Novo Nordisk’s Liraglutide Set For March 2009 PDUFA
Phase II study of once-weekly GLP-1 analog is under way, with results due next year.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.